ย
Victim of Severe Pradaxa Internal Bleeding Sues Drugmaker
By Andrea Gressman
ย
Ms. Champagne joins many other plaintiffs in the growing number of Pradaxa lawsuits currently consolidated into multidistrict litigation (MDL), which was established to expedite the large number of cases. The consolidation allows for a more streamlined litigation process than if each of the Pradaxa lawsuits were heard individually. The Pradaxa lawsuit MDL is currently being presided over by the Honorable Judge David R. Herndon.
Ms. Champagne alleges in her lawsuit that she was first prescribed Pradaxa in October of 2011. She was given the prescription to treat her condition of non-valvular atrial fibrillation. The Pradaxa lawsuit goes on to claim that on November 18, 2011, the plaintiff began to experience serious Pradaxa side effects including a severe gastrointestinal bleed in addition to bleeding ulcers. As a result of these Pradaxa side effects, Ms. Champagne had to spend 6 days in the hospital due to uncontrollable bleeding. The lawsuit alleges that the drug either caused the internal bleeding or made it worse, and the plaintiff seeks compensation for her injuries.
The Pradaxa lawsuit charges Boehringer Ingelheim with the following:
- Breach of express and implied warranties
- Design defect
- Failure to warn
- Fraudulent concealment
- Negligence
- Negligent misrepresentation
- Punitive damages
The plaintiff is seeking both compensatory and punitive damages in order to recover the costs that her Pradaxa side effects have generated.
Manufacturer Charged with Failure to Warn
Pradaxa has only been on the market for a short time. It was approved by the United States Food and Drug Administration (FDA) in October of 2010 in order to be another treatment option for those who needed a blood thinner to treat a variety of medical ailments. Upon receiving FDA approval, Boehringer Ingelheim heavily marketed the drug. In the first 2.5 months the drug manufacturer spent $67 million promoting the medication. By 2011 this figure was up to $464 million.
One of the allegations in the many Pradaxa lawsuits is that Boehringer falsely advertised the drug and made claims of effectiveness that were exaggerated when it came specifically to treating systemic embolism and strokes. The Pradaxa lawsuits also charge that Boehringer Ingelheim did not properly warn patients of the fact that there is not an antidote to reverse the internal bleeding that Pradaxa has been linked to causing. ย
Filing a Pradaxa Lawsuit
If you or someone you know experienced a Pradaxa side effect such as internal bleeding, hemorrhaging or a heart attack, you may be able to file a Pradaxa lawsuit as well as join the MDL. Visit theย Pradaxa Internal Bleeding Class Action Lawsuit Investigationย page to learn more about your legal rights. Simply provide your information and you can receive aย free legal reviewย from an experienced Pradaxa lawsuit lawyer.
Updated January 24th, 2013
ย
All medical device, dangerous drug and medical class action and lawsuit news updates are listed in the Drug and Medical Device section of Top Class Actions.
ย
Top Class Actions Legal Statement